Skip to main content
Clinical Trials/NCT02613312
NCT02613312
Terminated
Not Applicable

Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma

Mayo Clinic1 site in 1 country8 target enrollmentMarch 18, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mesothelioma
Sponsor
Mayo Clinic
Enrollment
8
Locations
1
Primary Endpoint
Overall Survival (OS)
Status
Terminated
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to determine the response rate and overall survival in patients that have been diagnosed with mesothelioma and will undergo chemotherapy, surgery and intensity modified radiation therapy (IMRT) as part of their standard of care.

Detailed Description

The investigators will consent patients that have been diagnosed with mesothelioma and will undergo chemotherapy followed by surgery and then IMRT as their standard of care. The investigators will collect data from past and future medical records as well as data regarding their health status for their lifetime by reviewing life status, treatment status and CT scans.

Registry
clinicaltrials.gov
Start Date
March 18, 2016
End Date
October 5, 2020
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dennis Wigle

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Subject provides informed consent
  • Subject is \>18 years of age
  • Subject is deemed competent for making medical decisions
  • Subject is scheduled to undergo chemotherapy followed by surgery and then IMRT
  • Subject is a surgical candidate
  • A negative pregnancy test is required in women of child-bearing potential, as standard of care.

Exclusion Criteria

  • Subject is \<18 years old.

Outcomes

Primary Outcomes

Overall Survival (OS)

Time Frame: 2 years

OS is defined as the length of time from study enrollment to death by any cause. Survival status of patients will be monitored every 6 months

Secondary Outcomes

  • Progression free survival (PFS) as evidenced by CT scan review(2 years)

Study Sites (1)

Loading locations...

Similar Trials